We review the recent literature on financing biomedical innovation, with a specific focus on
the drug development process and how it may be enhanced to improve outcomes. We begin …

Context: With the development of transformative drugs at a low point, numerous
commentators have recommended new legislation that uses supplementary market …

We investigate whether private research investments are distorted away from long-term
projects. Our theoretical model highlights two potential sources of this distortion: short …

Observers worry that generic patent challenges are on the rise and reduce the effective
market life of drugs. A related concern is that challenges disproportionately target high-sales …

Policy Points: Our study indicates that there are opportunities for cost savings in generic
drug markets in Europe and the United States. Regulators should make it easier for generic …

Recent evidence suggests that Medicare Part D increased prescription drug use among
seniors, and increased pharmaceutical firms' revenues from sales. Previous studies also …

Abstract Analysis of the timing of launches of 642 new drugs in 76 countries during 1983–
2002 shows that patent and price regulation regimes strongly affect how quickly new drugs …

This paper discusses contextual issues in sociotechnical systems and transitions under the
Multi Level Perspective (MLP). It emphasises inter system interactions, for which a typology …

The Hatch‐Waxman Act regulates competition between brand‐name and generic drugs in
the United States. We examine a feature of the Act that has attracted great controversy but …

Background Deployment of remote and virtual clinical trial methods and technologies,
referred to collectively as decentralized clinical trials (DCTs), represents a profound shift in …